Published in Mol Ther on November 19, 2015
HIV-Host Interactions: Implications for Vaccine Design. Cell Host Microbe (2016) 0.93
Novel Conserved-region T-cell Mosaic Vaccine With High Global HIV-1 Coverage Is Recognized by Protective Responses in Untreated Infection. Mol Ther (2016) 0.89
Epigraph: A Vaccine Design Tool Applied to an HIV Therapeutic Vaccine and a Pan-Filovirus Vaccine. Sci Rep (2016) 0.86
Polyvalent vaccine approaches to combat HIV-1 diversity. Immunol Rev (2017) 0.77
Broad HIV-1 inhibition in vitro by vaccine-elicited CD8(+) T cells in African adults. Mol Ther Methods Clin Dev (2016) 0.77
HIV-1 Conserved Mosaics Delivered by Regimens with Integration-Deficient DC-Targeting Lentiviral Vector Induce Robust T Cells. Mol Ther (2017) 0.75
Mosaic H5 Hemagglutinin Provides Broad Humoral and Cellular Immune Responses against Influenza Viruses. J Virol (2016) 0.75
Heterologous prime-boost vaccination with DNA and MVA vaccines, expressing HIV-1 subtype C mosaic Gag virus-like particles, is highly immunogenic in mice. PLoS One (2017) 0.75
HIV-1-neutralizing antibody induced by simian adenovirus- and poxvirus MVA-vectored BG505 native-like envelope trimers. PLoS One (2017) 0.75
Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol (1994) 22.96
Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol (1994) 15.93
A whole-genome association study of major determinants for host control of HIV-1. Science (2007) 15.19
Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science (1998) 12.05
Simple and highly efficient BAC recombineering using galK selection. Nucleic Acids Res (2005) 11.23
HIV evolution: CTL escape mutation and reversion after transmission. Nat Med (2004) 10.21
Diversity considerations in HIV-1 vaccine selection. Science (2002) 9.60
Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature (2011) 9.30
Evolution and transmission of stable CTL escape mutations in HIV infection. Nature (2001) 6.57
The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J Exp Med (2009) 6.22
Evolutionary and immunological implications of contemporary HIV-1 variation. Br Med Bull (2001) 4.41
Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nat Med (2006) 4.14
Cytotoxic T-cell activity antagonized by naturally occurring HIV-1 Gag variants. Nature (1994) 3.97
Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys. Nat Med (2010) 3.44
Clustering patterns of cytotoxic T-lymphocyte epitopes in human immunodeficiency virus type 1 (HIV-1) proteins reveal imprints of immune evasion on HIV-1 global variation. J Virol (2002) 3.38
Covariation of mutations in the V3 loop of human immunodeficiency virus type 1 envelope protein: an information theoretic analysis. Proc Natl Acad Sci U S A (1993) 3.20
Immune clearance of highly pathogenic SIV infection. Nature (2013) 3.15
HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice. J Exp Med (1997) 3.03
Peptide selection for human immunodeficiency virus type 1 CTL-based vaccine evaluation. Vaccine (2006) 2.89
Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys. Cell (2013) 2.88
Design and pre-clinical evaluation of a universal HIV-1 vaccine. PLoS One (2007) 2.61
Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys. Nat Med (2010) 2.53
Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations. Nature (2015) 2.41
HIV-1 group M conserved elements vaccine. PLoS Pathog (2007) 2.28
T-cell vaccine strategies for human immunodeficiency virus, the virus with a thousand faces. J Virol (2009) 2.17
Translating HIV sequences into quantitative fitness landscapes predicts viral vulnerabilities for rational immunogen design. Immunity (2013) 2.00
T cell cross-reactivity and conformational changes during TCR engagement. J Exp Med (2004) 1.99
Definition of the viral targets of protective HIV-1-specific T cell responses. J Transl Med (2011) 1.73
Characterization and selection of HIV-1 subtype C isolates for use in vaccine development. AIDS Res Hum Retroviruses (2003) 1.68
Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1. Mol Ther (2013) 1.61
Expanded breadth of the T-cell response to mosaic human immunodeficiency virus type 1 envelope DNA vaccination. J Virol (2008) 1.51
Modulation of DNA vaccine-elicited CD8+ T-lymphocyte epitope immunodominance hierarchies. J Virol (2006) 1.49
Immunodominance in virus-induced CD8(+) T-cell responses is dramatically modified by DNA immunization and is regulated by gamma interferon. J Virol (2002) 1.42
Protective efficacy of serially up-ranked subdominant CD8+ T cell epitopes against virus challenges. PLoS Pathog (2011) 1.27
Long peptides induce polyfunctional T cells against conserved regions of HIV-1 with superior breadth to single-gene vaccines in macaques. Eur J Immunol (2010) 1.27
Combined approaches for HIV cure. Curr Opin HIV AIDS (2013) 1.23
The T-cell response to HIV. Cold Spring Harb Perspect Med (2012) 1.20
Breadth of cellular and humoral immune responses elicited in rhesus monkeys by multi-valent mosaic and consensus immunogens. Virology (2012) 1.12
Genotype 1 and global hepatitis C T-cell vaccines designed to optimize coverage of genetic diversity. J Gen Virol (2010) 1.05
Conserved immunogens in prime-boost strategies for the next-generation HIV-1 vaccines. Expert Opin Biol Ther (2014) 1.05
Combined single-clade candidate HIV-1 vaccines induce T cell responses limited by multiple forms of in vivo immune interference. Eur J Immunol (2007) 0.98
Optimizing HIV-1-specific CD8+ T-cell induction by recombinant BCG in prime-boost regimens with heterologous viral vectors. Eur J Immunol (2011) 0.95
Modified H5 promoter improves stability of insert genes while maintaining immunogenicity during extended passage of genetically engineered MVA vaccines. Vaccine (2009) 0.94
Designing and testing broadly-protective filoviral vaccines optimized for cytotoxic T-lymphocyte epitope coverage. PLoS One (2012) 0.92
Broad protection against avian influenza virus by using a modified vaccinia Ankara virus expressing a mosaic hemagglutinin gene. J Virol (2014) 0.90
Clinical Control of HIV-1 by Cytotoxic T Cells Specific for Multiple Conserved Epitopes. J Virol (2015) 0.86
Hepatitis C genotype 1 mosaic vaccines are immunogenic in mice and induce stronger T-cell responses than natural strains. Clin Vaccine Immunol (2012) 0.84
TAPBPR alters MHC class I peptide presentation by functioning as a peptide exchange catalyst. Elife (2015) 0.84
Control of HIV-1 replication in vitro by vaccine-induced human CD8(+) T cells through conserved subdominant Pol epitopes. Vaccine (2016) 0.81
Characterization of T-cell responses to conserved regions of the HIV-1 proteome in BALB/c mice. Clin Vaccine Immunol (2014) 0.81
Plasticity of empty major histocompatibility complex class I molecules determines peptide-selector function. Mol Immunol (2015) 0.81
Short conserved sequences of HIV-1 are highly immunogenic and shift immunodominance. J Virol (2014) 0.81